Focus Partners Advisor Solutions LLC Acquires Shares of 849 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Focus Partners Advisor Solutions LLC acquired 849 shares of Regeneron Pharmaceuticals valued at approximately $538,000 during Q1, signaling new investor interest in the biopharmaceutical company.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the latest quarter, exceeding estimates of $8.43 and demonstrating a year-over-year revenue increase of 3.6%.
• The company recently declared a quarterly dividend of $0.88 per share, with an annualized yield of 0.6% and a payout ratio of 8.87%.

Focus Partners Advisor Solutions LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 849 shares of the biopharmaceutical company's stock, valued at approximately $538,000.

Several other hedge funds also recently modified their holdings of the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Finally, Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.1%

REGN traded up $6.16 during mid-day trading on Friday, reaching $573.38. 959,753 shares of the stock were exchanged, compared to its average volume of 946,607. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock has a market capitalization of $60.77 billion, a PE ratio of 14.45, a price-to-earnings-growth ratio of 1.92 and a beta of 0.35. The company has a 50 day moving average price of $562.59 and a two-hundred day moving average price of $583.92. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $11.56 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.